{"schema_version":"secwatch.filing_event.v1","accession":"0001401914-22-000085","form_type":"8-K","ticker":"DARE","cik":"0001401914","company_name":"Dare Bioscience, Inc.","filed_at":"2022-11-10T23:59:59+00:00","discovered_at":"2026-05-14T18:03:50.463738+00:00","generated_at":"2026-06-21T22:38:09.240652+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Daré Q3 cash $40.4M; Ovaprene IDE approved; DARE-HRT1 positive efficacy data","bullets":["Cash $40.4M at Sep 30, 2022 vs $51.7M Dec 31, 2021; R&D expense $4.5M (down from $10.4M).","FDA approved IDE for Ovaprene pivotal Phase 3 contraceptive study; investigator meeting Dec 2022.","Positive topline efficacy data from DARE-HRT1 Phase 1/2 study; PK data expected later Q4 2022.","Sildenafil Cream 3.6% Phase 2b RESPOND subject screening completed; topline data targeted Q2 2023.","XACIATO first commercial sale expected 1H 2023 under Organon license agreement."],"urls":{"canonical":"https://secwatch.observer/filing/0001401914-22-000085","json":"https://secwatch.observer/filing/0001401914-22-000085.json","markdown":"https://secwatch.observer/filing/0001401914-22-000085.md","text":"https://secwatch.observer/filing/0001401914-22-000085.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/0001401914-22-000085-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/dare-20221110.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T22:38:09.240652+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"82ab3c6619344c24fd1ba32b0ebd2b6a3c640655","claim":"Dare Bioscience, Inc. reported financial results for the third quarter ended September 30, 2022.","evidence_excerpt":"On November 10, 2022, Dare Bioscience, Inc. issued a press release announcing its financial results for the third quarter ended September 30, 2022.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1401914/000140191422000085/0001401914-22-000085-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the third quarter ended September 30, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}